<?xml version="1.0" encoding="UTF-8"?>
<notes id="n1">
 <title>Notes</title>
 <p>
  <bold>
   <italic>Financial support.</italic>
  </bold> This work was supported by William H. Goodwin and Alice Goodwin, the Commonwealth Foundation for Cancer Research and the Center for Experimental Therapeutics at Memorial Sloan Kettering Cancer Center, the Carson Family Charitable Trust, the Emerald Foundation, the Annual Terry Fox Run for Cancer Research organized by the Canada Club of New York, Kate’s Team, the William Lawrence and Blanche Hughes Foundation, the Lake Road Foundation, Juno Therapeutics, National Institutes of Health/National Cancer Institute Cancer Center Support Grant (P30 CA008748), the American Society of Clinical Oncology (J. H. P.), the Leukemia and Lymphoma Society (J. H. P.), and the National Comprehensive Cancer Network (J. H. P.).
 </p>
 <p>
  <bold>
   <italic>Potential conflicts of interest.</italic>
  </bold> J. H. P. reports connections with Amgen (consulting/advisory role), Juno Therapeutics (research funding), Genentech/Roche (research funding), and Pfizer (consulting/advisory role). M. S. and R. J. B. report connections with Juno Therapeutics (consulting/advisory role, royalty sharing agreement, and stock ownership for both; research funding for R. J. B.). All other authors report no potential conflicts of interest. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.
 </p>
</notes>
